Congress funds research into cancer disparity killing Black women
H.R. 5239 — Endometrial Cancer Research and Education Act of 2025 · Filed by David Scott (D-GA) · 8 cosponsors · Introduced Sep 9, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health (NIH) to expand research into endometrial cancer and ensure African-American women are represented in clinical trials proportional to their disease incidence, while the CDC develops and distributes public education materials about the disease, its risk factors, and treatments. The bill authorizes $1 million annually for NIH research (2026–2028) and unspecified CDC funding to address documented disparities in endometrial cancer diagnosis and mortality between African-American and white women.
Why we flagged it
The bill's core function is to expand federally funded research into a specific cancer type and address documented health disparities through clinical trial representation and public education—standard public health legislation with an explicit equity focus.
What the text implies
- Mandating proportional African-American representation in NIH-supported endometrial cancer trials may establish a precedent for equity-based clinical trial design across other disease areas, potentially shifting how NIH allocates research resources.
- The bill's emphasis on investigating delays in care and socioeconomic barriers may indirectly pressure healthcare systems and insurers to examine their own access and treatment protocols, though enforcement mechanisms are not specified.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies developing endometrial cancer treatments; research institutions and universities conducting NIH-funded studies; healthcare systems and oncology practices treating endometrial cancer